According to three people familiar with the matter, Brazil is battling bureaucracy in China to free up exports of active ingredients for vaccines developed by AstraZeneca and Sinovac, as reported in Fidelity.
On Tuesday, more Brazilian states administered their first COVID-19 vaccinations, as the government distributed some 6 million ready doses of the vaccine from Sinovac after its approval for emergency use on January 17.
However, sources said red tape in China was holding back supplies needed for Brazil to finish and distribute millions more doses from its own biomedical facilities.
"It's a new situation, and there's a bureaucratic problem. The Chinese are still defining procedures, which takes time," one source said, adding "there's also a relative scarcity of supplies."
AstraZeneca has arranged for substantial manufacturing of its vaccine's active ingredients in China, the news source said.
Last month, Brazilian health inspectors visited and approved the facilities of Chinese firm WuXi Biologics to export the ingredients of the AstraZeneca vaccine for finishing in Brazil.
To read more NewsPoints articles, click here.